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Abstract
Background: Estrogens exert a role on germ cell physiology of normal human testis through the
mediation of the estrogen receptor (ER) beta subtypes. Epidemiological studies evidenced an
increased incidence of testicular germ cell cancer after elevated pre-natal estrogen exposure but
the expression of estrogen receptors in these testicular neoplasms has not been well elucidated.
Methods:  Immunohistochemistry and Western blot analysis were used to investigate the
expression of three distinct ER isoforms, ERalpha, ERbeta1, and ERbeta2 in paraffin-embedded
tissues from seminomas and embryonal carcinomas, which are the most common testicular germ
cell tumours.
Results:  Neoplastic cells of all specimens revealed a positive ERbeta1 and ERbeta2
immunoreactivity, while the ERalpha signal was undetectable. A similar pattern of estrogen
receptor immunostaining was also observed in the malignant germ cells of intratubular germ cell
neoplasia, adjacent to testicular cancers. Western blot analysis of tumour extracts revealed two
immunoreactive bands, a 59 kDa band for ERbeta1 and a 53 kDa band for ERbeta2.
Conclusion: A variable ERbeta expression was previously reported in testicular germ cell tumours
and, particularly, an ERbeta down-regulation was evidenced in seminoma and embryonal
carcinoma. Conversely, the current study has clearly identified ERbeta1 and ERbeta2 in the
neoplastic cells of seminoma and embryonal carcinoma, as well as in the malignant cells of their
common pre-invasive precursor, intratubular germ cell neoplasia. Therefore, our findings suggest
that ERbeta1, together with a possible ERbeta2 contribute, can mediate estrogen action in both
early and late neoplastic testicular germ cells, not confirming the previously hypothesized
antiproliferative effect of ERbeta on male gonadal cells.
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Background
A current worldwide rise in the incidence of testicular
germ cell cancer has been evidenced by epidemiological
studies [1]. However, despite of growing researches on
pathogenesis of these testicular neoplasms, lots of gaps of
knowledge remain on molecular mechanisms responsible
for the tumorigenesis process [2].
An increased rate of testicular germ cell tumours, after pre-
natal estrogen exposure, has supported the hypothesis
that these hormones could play a role in the male gonadal
carcinogenesis in combination with genetic susceptibility
[3-6]. On the other hand, the recognized ability of estro-
gens to regulate cell growth and apoptosis [7,8] could be
involved in testicular neoplastic proliferation.
Estrogens exert their pleiotropic and tissue-specific effects
through the differential expression of distinct estrogen
receptors, ERα and ERβ, and their coregulators [9].
In normal human testis, estrogen receptor-β is known as
the mediator of physiological estrogen action. Testicular
somatic and germ cells express mainly the two isoforms
ERβ1 and ERβ2 [10-12]. ERβ1 is the full length wild type
ERβ and the only fully functional isoform [13] while ERβ2
is a splice variant, lacking aminoacid essential for binding
estradiol [14]. Mediation of estrogen signalling is deter-
mined by differential dimerization of ERs and a recent
study indicated that ERβ2 can heterodimerize with ERβ1
and enhance its transactivation in a ligand-dependent
manner [13]. However, the distinct biological roles of the
ERβ isoforms is still undefined [15].
In testicular germ cell tumours the expression of estrogen
receptors has not been still clarified. In fact, a highly vari-
able ERβ expression has been reported in the different
tumour types [16].
Therefore, with the aim to expand the ER knowledge in
male gonadal neoplasms, the present work investigated
the expression of three distinct ER isoforms (ERα, ERβ1
and ERβ2) in testicular tissues from patients with semi-
noma and embryonal carcinoma, which are the most
common cancers in young men.
Methods
Patients
The investigation has been performed on formalin-fixed
and paraffin-embedded testis tissues from 16 male
patients (ages 20 – 35 years) with pure seminoma (n = 10)
and pure embryonal carcinoma (n = 5) undergoing to
therapeutic orchidectomy. Control testicular tissues were
obtained from 2 male patients (ages 29 and 35 years)
showing testes with a like-Sarcoidosis granulomatous
lesion. The archival cases were provided by the Pathologic
Anatomy Unit (Annunziata Hospital, Cosenza, Italy). The
ethical committee members of the University of Calabria
approved the investigation programme.
Histopathological analysis
Morphological studies were carried out by Haematoxylin-
Eosin staining. Testis tumour samples were also investi-
gated by placental-like alkaline phosphatase (PLAP)
immunohistochemistry, using the anti- human PLAP as
primary antibody (30 minutes at RT) followed by the avi-
din-biotin-horseradish peroxidase complex (ABC/HRP)
and diaminobenzidine visualization.
Chemicals
The reagents were purchased from Sigma Aldrich (Milan,
Italy), unless otherwise indicated.
Antibodies
Anti-ERα primary antibody was mouse monoclonal F-10
(Santa Cruz Biotechnology, California, USA) which recog-
nizes epitope mapping at the C-terminus region of the
human native ERα. Anti-ERβ primary antibody was rabbit
polyclonal H150 (Santa Cruz Biotechnology, California,
USA) which recognizes epitope mapping at the N-termi-
nus regions of human native ERβ. Anti-ERβ1 primary anti-
body was mouse monoclonal MCA1974S (Serotec,
Oxford, UK) which recognizes epitope mapping at the C-
terminus regions of human native ERβ1 while anti-ERβ2
primary antibody was mouse monoclonal MCA2279S
(Serotec, Oxford, UK) which recognizes epitope mapping
at the C-terminus regions of human native ERβ2. Anti
human PLAP antibody was monoclonal mouse, clone
8A9, (DAKO-Cytomation, Milan, Italy). Rabbit polyclo-
nal anti β-actin (Santa Cruz Biotechnology, California,
USA) was also used as loading control. Biotinylated goat-
anti-mouse IgG (Vector Laboratories, INC, Burlingame,
California, USA), goat anti-rabbit horseradish peroxidase
conjugated IgG (Amersham, USA) and goat anti-mouse
horseradish peroxidase conjugated IgG (Amersham, USA)
were used as secondary antibodies.
Immunohistochemical analysis
Paraffin embedded sections, 5 μm thick, were mounted
on slides precoated with poly-lysine, and then they were
deparafinized and dehydrated (7–8 serial sections).
Immunohistochemical experiments were performed after
heat-mediated antigen retrieval in 0.01 M citrate buffer,
pH 6. Hydrogen peroxide (3% in distillate water) was
used, for 30 minutes, to inhibit endogenous peroxidase
activity while normal goat serum (10%) was utilised, for
30 minutes, to block the non-specific binding sites.
Immunodetection was carried out using anti-ERα (1:50),
anti-ERβ1 and anti-ERβ2 (1:100) primary antibodies at
4°C overnight. Then, a biotinylated goat-anti-mouse IgGReproductive Biology and Endocrinology 2009, 7:56 http://www.rbej.com/content/7/1/56
Page 3 of 9
(page number not for citation purposes)
was applied (1:600) for 1 hour at RT, followed by the avi-
din-biotin-horseradish peroxidase complex (ABC/HRP)
(Vector, Laboratories, CA, USA). Immunoreactivity was
visualized by using the diaminobenzidine chromogen
(DAB)(Zymed Laboratories, CA, USA). Testis sections
were also counterstained with haematoxylin. The primary
antibody was replaced by normal rabbit serum in negative
control sections. Absorption controls have utilised pri-
mary antibodies preabsorbed with an excess (5 nmol/ml)
of the purified respective blocking peptides (Santa Cruz
Biotechnology, Ca, USA), at 4°C for 48 hours. Breast can-
cer tissue was used as positive control for ERα, while con-
trol human testis was used as positive control for both
ERβ1 and ERβ2. Six-seven serial sections were processed
for each sample.
Scoring system
The immunostained slides were examined by light micro-
scopy using the "Allred Score" [17], which combines a
proportion score and an intensity score. A proportion
score was assigned representing the estimated proportion
of positively stained tumour cells (0 = none; 1 = <1/100;
2 = 1/100 to <1/10; 3 = 1/10 to <1/3; 4 = 1/3 to 2/3; 5 =
>2/3). An intensity score was assigned by the average esti-
mated intensity of staining in positive cells (0 = none; 1 =
weak; 2 = moderate; 3 = strong). Proportion score and
intensity score were added to obtained a total score that
ranged from 0 to 8. A minimum of 100 cells were evalu-
ated in each slide. Six-seven serial sections were scored for
each sample. The one-way ANOVA was used to evaluate
the differences in the scores between tumoral and control
samples.
Protein extraction
Protein extraction from formalin-fixed paraffin-embed-
ded sections has been carried out according to Ikeda [18].
Briefly, 50 μm testis sections were deparaffinized in
xylene, dehydrated in graded ethanol, immersed in dis-
tilled water, and air dried. Then, the neoplastic area was
recovered from the glass slides, further it was cut into
small pieces and placed in Eppendorf tubes. Two hundred
μl of RIPA buffer, pH 7,6 (1 M NaH2PO4, 10 mM
Na2HPO4, 154 mM NaCl, 1% Triton X-100, 12 mM
C24H39O4Na, 0,2% NaN3, 0,95 mM NaF, 2 mM PMSF, 50
mg/ml aprotinin, 50 mM leupeptin) containing 0,2%
SDS, was added to each tube and the contents were incu-
bated at 100°C for 20 minutes, followed by incubation at
60°C for 2 hours. After incubation, tissue lysates were
centrifuged at 15,000 × g for 20 minutes at 4°C and the
supernatants were stored at -80°C until biochemical anal-
ysis.
Western blot analysis
Tissue lysates were quantified using Bradford protein
assay reagent [19]. Equal amounts of protein (50 μg) were
boiled for 5 minutes, separated under denaturing condi-
tions by SDS-PAGE on 10% polyacrylamide Tris-glycine
gels and electroblotted to nitrocellulose membrane. Non-
specific sites were blocked with 5% non fat dry milk in
0.2% Tween-20 in Tris-buffered saline (TBS-T) for 1 hour
at room temperature and incubated overnight with anti-
ERα(F-10) (1:500), anti-ERβ(H150) (1:500), anti-actin
(1:1000) primary antibodies. The antigen-antibody com-
plexes were then detected by incubation of the mem-
branes for 1 hour at 22°C with the horseradish
peroxidase-conjugated secondary antibodies (1:7000).
The bound secondary antibodies were located with the
ECL Plus Western blotting detection system (Amersham,
USA) according to the manufacturer's instruction. Each
membrane was exposed to the film for 2 minutes.
Protein extracts from cultured MCF7 (breast cancer cell
line) and LnCap (prostate cancer cell line) cells were used
as positive controls for ERα and ERβ respectively. Cells
were maintained at 37°C in a humidified atmosphere of
5% CO2 in air and were cultured in DMEM-F12 (MCF-7
cells) or in RPMI-1640 medium (LnCap cells) supple-
mented with L-glutamine (2 mM), penicillin (100 U/ml),
streptomycin (100 U/ml), and 10% fetal bovine serum
(Life Technology, Milan, Italy)
Negative controls were prepared using tissue lysates,
where antigens were previously removed by pre-incuba-
tion with specific antibodies (1 hour at room tempera-
ture) and subsequently immunoprecipitated with protein
A/G -agarose.
Results
Histopathological study
Seminoma
Morphological analysis of pure seminoma samples
(stages I) showed the presence of typical tumoral tissues
with uniform populations of large neoplastic cells which
were arranged in diffuse sheets separated by thin septae.
Extensive leukocyte infiltrations were observed in all sam-
ples (Fig 1A shows a representative sample).
Embryonal carcinoma
Tumoral tissues of pure embryonal carcinoma showed
nodular areas surrounded by connective tissue. The large
neoplastic cells had ill-defined borders, big nuclei, pale
cytoplasms and were mainly arranged in glandular pat-
tern. Plurinuclear cells were also present (Fig 1 A1 shows
a representative sample).
IGCN
The regions adjacent to seminoma (70% of samples) and
to embryonal carcinoma (60% of samples) have shown
the presence of seminiferous tubules lacking sperma-
togenesis, which were identified as intratubular germ cellReproductive Biology and Endocrinology 2009, 7:56 http://www.rbej.com/content/7/1/56
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neoplasia (IGCN), unclassified type. These intratubular
lesions were characterized by the basal proliferation of
undifferentiated atypical enlarged germ cells, with big
nuclei, and by the presence of Sertoli cells in luminal dis-
placement. Cytoplasmic and membranous dark staining
have revealed the PLAP immunopositivity in the malig-
nant cells aligned along the basal portion of seminiferous
tubules (Fig 2A, B), indicating their germ cell origin.
Immunohistochemistry
Immunostainings of all seminoma and embryonal carci-
noma specimens revealed an intense nuclear ERβ1 and
ERβ2 immunoreactivity of neoplastic cells while the leu-
kocytes were immunonegative (Fig 1:B, C, B1, C1)
As expected, in control testis sections the cells of tubular
and interstitial compartments showed strong exclusively
nuclear ERβ1 and ERβ2 immunostainings (Fig 1:B2, C2).
ERα signal was totally absent in control and tumoral tes-
tes) (Fig 3A, B, C).
Table 1 shows the intensity staining scores of tumoral and
control samples. Statistical analysis evidenced that ERβ1
score of seminomas was higher than ERβ1 score of control
testes (p < 0.05).
In addition, neoplastic cells of intratubular germ cell neo-
plasia (IGCN), adjacent to seminoma and embryonal car-
cinoma, revealed a positive ERβ1 and ERβ2
Morphology and immunolocalization of estrogen receptors (ERβ1, ERβ2) in seminoma, embryonal carcinoma and control testis Figure 1
Morphology and immunolocalization of estrogen receptors (ERβ1, ERβ2) in seminoma, embryonal carcinoma 
and control testis. The pictures show representative samples. A, A1, A2: Haematoxylin-Eosin staining. B, B1, B2: ERβ1 
immunolocalization. C, C1, C2: ERβ2 immunodetection. Scale bars = 12,5 m μ. L, linfocytes. Lc, Leydig cell. Nc, neoplastic cell. 
Pc, plurinuclear cell. S, septa. T, seminiferous tubule. Inserts at the bottom right side (B, B1, B2, C, C1, C2): absorption con-
trols. Scale bars = 12,5 mμ. Inserts at the top right side (B, B1, C, C1): higher magnification of the pictures. Scale bars = 5 mμ.Reproductive Biology and Endocrinology 2009, 7:56 http://www.rbej.com/content/7/1/56
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PLAP staining and immunolocalization of estrogen receptors (ERβ1, ERβ2) in intratubular germ cell neoplasia adjacent to sem- inoma (A) and embryonal carcinoma(B); the pictures show representative samples Figure 2
PLAP staining and immunolocalization of estrogen receptors (ERβ1, ERβ2) in intratubular germ cell neoplasia 
adjacent to seminoma (A) and embryonal carcinoma(B); the pictures show representative samples. A, B: PLAP 
staining. A1, B1: ERβ1 immunolocalization. A2, B2: ERβ2 immunodetection. Ncg, neoplastic germ cell. Sc, Sertoli cell. Scale bars 
= 5 mμ.
Immunolocalization of ERα in seminoma (A), embryonal carcinoma(B) and control testis (C); the pictures show representative  samples Figure 3
Immunolocalization of ERα in seminoma (A), embryonal carcinoma(B) and control testis (C); the pictures 
show representative samples. L, linfocytes. Lc, Leydig cells. Nc, neoplastic cell. T, seminiferous tubules. Scale bars = 12,5 
mμ.Reproductive Biology and Endocrinology 2009, 7:56 http://www.rbej.com/content/7/1/56
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immunostaining (Fig 2: A1, A2, B1, B2) but no ERα
immunoreactivity (data not shown).
All tissues used as positive controls showed a strong ERα/
ERβ1/ERβ2 immunoreactivity (data not shown). Further-
more, negative controls (data not shown) and absorption
controls (inserts) were all immunonegative.
Western blot analysis
For WB analysis of tumour extracts we have used a single
ERβ antibody which was tested for this application. This
anti-ERβ antibody, mapping at the N-terminus region of
human native ERβ, let us to reveal both the ERβ subtypes.
In fact, the immunoblots of seminoma and embryonal
carcinoma extracts showed a thick ERβ1 band at ~59 kDa
and a thin ERβ2 band ~53 kDa (Fig 4B: lanes 1, 2). Similar
bands were observed in the LnCap cell extract, used as
positive control (Fig 4B: lane C). Conversely, using an
antibody against ERα, no protein band has been observed
in the immunoblots of tumoral testes (Fig 4A: lanes 1, 2),
while MCF7 cell extract (positive control) showed the
classical ~67 kDa band (Fig 4A: lane C). As expected, con-
trol testes showed the ~59 kDa ERβ1 band and the ~53
kDa ERβ2 band (Fig 4B: lane 3) but not the ERα band (Fig
4A: lane 3)All the negative control lanes were unlabelled
(data not shown).
Discussion
Testicular germ cell tumours are joined to cryptorchidism,
hypospadias and impaired spermatogenesis in the "testic-
ular dysgenesis syndrome" (TDS), which includes disor-
ders resulting from the impairment of fetal gonadal
development [20]. In normal human testis, fetal gono-
cytes change into neonatal spermatogonia which mature
into viable sperm after puberty. Conversely, testicular
germ cell tumours appear to arise from abnormal gono-
cytes which arrest their differentiation, undergoing a
malignant transformation [21,22].
Increased estrogen exposure could be an important aetio-
logical factor to promote the TDS disorders and particu-
larly testis cancer [6], but the related molecular
mechanisms remain to be elucidated.
Estrogen receptors orchestrate both transcriptional and
non genomic cellular responses to estrogens. Therefore,
they are involved in physiological germ cell differentia-
tion, but, at the same time, they could mediate the estro-
gen signalling on malignant germ cell proliferation,
probably damaging DNA such as reported in breast cancer
[23].
Estrogen receptor-β mediates physiological estrogen
action in somatic and germ cells of normal human testis
[10-12], but its possible involvement in estrogen-induced
carcinogenicity has been also reported. In fact, experimen-
tal estrogen exposure of rat testis resulted in oxidative
DNA damage via an ERβ-mediated process [24].
The present work has identified ERβ1 and ERβ2 in neo-
plastic cell nuclei of seminoma and embryonal carci-
noma, which are the most common testicular germ cell
tumours. Agreeing with Saunders's report [11], a nuclear
staining of the two ERβ isoforms has been also observed
in control germ cells. Western blot analysis of tumour
extracts confirmed these findings showing two protein
bands consistent with the ERβ1 and ERβ2 molecular
weights.
Two previous studies detected differentially ERβ1 in testic-
ular germ cell tumours. In fact, ERβ expression was strong
in endoderma sinus tumour and in teratoma [16] but it
was low in seminoma and in embryonal carcinoma
[16,25]. Furthermore, a punctuate cytoplasmic ERβ local-
ization has been reported in three seminoma tumoral
fragments as well as in seminoma cell line (JKT-1) [26].
Therefore, previous data are conflictual with respect to our
results which have evidenced a remarkable and
undoubted ERβ1 and ERβ2 immunoreactivity in the
nuclei of seminoma and embryonal carcinoma cells.
These discrepancies could be due to the variability in pro-
tein expression of different tumour samples and/or to the
use of different antibodies. Despite of previous studies,
the present investigation has performed immunohisto-
chemical experiments using primary antibodies which
were specific for each of the two ERβ isoforms and tested
for imminohistochemistry.
Table 1: Immunostaining scores (Allred score) of ERβ1 and ERβ2 
in tumoral and control testes
Groups ERbeta1 ERbeta2
seminoma
Patient 1 8 7
" 2 6 5
" 3 7 6
" 4 7 6
" 5 7 6
" 6 8 6
" 7 7 7
" 8 8 5
" 9 7 6
" 10 8 6
embryonal carcinoma
Patient 1 6 5
" 2 6 5
" 3 7 6
" 4 7 5
" 5 7 6
control testis
Patient 1 6 5
" 2 6 5
Immunostained slides scores as follows: Total score= Proportion 
score+ Intesity score (range 0–8)Reproductive Biology and Endocrinology 2009, 7:56 http://www.rbej.com/content/7/1/56
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Our data do not support a possible role of the ERβ down
regulation in testicular tumorigenesis as hypothesized by
the previous authors; however, as these results are con-
flictual, further studies need to confirm them.
In addition, our work has shown the ERβ1 and ERβ2
expression in the big neoplastic cells (recognized by
PLAP) of IGCN which are considered the pre-invasive pre-
cursors of testicular germ cell tumours. In fact, phenotypic
similarity of IGCN cells with fetal gonocytes, embryonic
stem cells and primordial germ cells [20,27-29] suggested
that IGCN cells are originated from the arrest of fetal germ
cell differentiation followed by malignant transforma-
tion. Therefore, our paper has revealed, for the first time,
the expression of ERβ1 and ERβ2 in the early stages of tes-
ticular tumorigenesis process. Interestingly, the two ERβ
isoforms were identified in human fetal gonocytes [30],
but with a clear prevalence of ERβ2 on ERβ1.
Previous studies from our laboratory demonstrated aro-
matase expression in tumoral cells of seminoma and adja-
cent IGCN [31], as well as in embryonal carcinoma
[unpublished data], indicating a local estrogen produc-
tion. In the current study, seminoma and embryonal car-
cinoma cells, expressing ERβ1 and ERβ2 but not ERα,
have shown an ER pattern similar to that one of normal
testicular cells. A high ERβ1 immunoreactivity of semi-
noma cells has been detected, but this new finding needs
to be confirmed in a larger size of sample set, before spec-
ulating its involvement in the autocrine/paracrine estro-
gen action promoting testicular germ cell malignancies.
Conversely, our recent paper evidenced an altered ER
expression pattern in two human Leydig cell tumours,
suggesting the possible contribute of the unexpected ERα
presence to the tumour cell growth and progression [32].
A recent work [33] suggested that estrogens could contrib-
ute to human testicular germ cell cancer proliferation by a
rapid activation of ERK1/2 and PKA through a non classi-
cal membrane ER. Therefore, further studies will be neces-
sary to expand the knowledge of estrogen signalling
involved in testicular tumorigenesis.
Immunoblots of estrogen receptors (ERα, ERβ1, ERβ2) from representative protein extracts of seminoma and embryonal car- cinoma Figure 4
Immunoblots of estrogen receptors (ERα, ERβ1, ERβ2) from representative protein extracts of seminoma and 
embryonal carcinoma. ERα immunoblot (A): MCF7 cultured cells (C), seminoma (lane 1), embryonal carcinoma (lane 2) and 
control testis (lane 3). ERβ1- ERβ2 immunoblot (B): LnCap cultured cells (C), seminoma (lane 1), embryonal carcinoma (lane2) 
and control testis (lane 3). β-actin serves as a loading control. Numbers on the left-hand side correspond to the standard 
molecular weights Numbers on the right-hand side correspond to molecular weights of the detected protein.Reproductive Biology and Endocrinology 2009, 7:56 http://www.rbej.com/content/7/1/56
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Conclusion
The present study has demonstrated the expression of
ERβ1 and ERβ2 in seminoma and embryonal carcinoma
cells, as well as in neoplastic cells of their pre-invasive pre-
cursor, IGCN. Therefore, our findings suggest that the two
ERβ subtypes can mediate estrogen action in both early
and late neoplastic testicular germ cells, not confirming a
possible suppressive role of ERβ on male gonadal cell pro-
liferation, as previously hypothesized.
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